Literature DB >> 22542019

Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.

Garry R Smith1, Dejan Caglič, Petr Capek, Yan Zhang, Sujata Godbole, Allen B Reitz, Tobin J Dickerson.   

Abstract

Botulinum neurotoxins (BoNTs) are the most toxic proteins known to man, exposure to which results in flaccid paralysis. Given their extreme potency, these proteins have become studied as possible weapons of bioterrorism; however, effective treatments that function after intoxication have not progressed to the clinic. Here, we have reexamined one of the most effective inhibitors, 2,4-dichlorocinnamyl hydroxamate, in the context of the known plasticity of the BoNT/A light chain metalloprotease. Our studies have shown that modifications of this compound are tolerated and result in improved inhibitors, with the best compound having an IC(50) of 0.23 μM. Given the inconsistency of structure-activity relationship trends observed across similar compounds, this data argues for caution in extrapolating across structural series.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542019      PMCID: PMC3352981          DOI: 10.1016/j.bmcl.2012.04.019

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

1.  Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction.

Authors:  Y Liu; W Kati; C M Chen; R Tripathi; A Molla; W Kohlbrenner
Journal:  Anal Biochem       Date:  1999-02-15       Impact factor: 3.365

2.  Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry.

Authors:  Grant E Boldt; Jack P Kennedy; Kim D Janda
Journal:  Org Lett       Date:  2006-04-13       Impact factor: 6.005

3.  Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore.

Authors:  Ann R Hermone; James C Burnett; Jonathan E Nuss; Lyal E Tressler; Tam L Nguyen; Bogdan A Solaja; Jonathan L Vennerstrom; James J Schmidt; Peter Wipf; Sina Bavari; Rick Gussio
Journal:  ChemMedChem       Date:  2008-12       Impact factor: 3.466

Review 4.  The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison.

Authors:  Bert Willis; Lisa M Eubanks; Tobin J Dickerson; Kim D Janda
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

5.  Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors.

Authors:  Grant E Boldt; Jack P Kennedy; Mark S Hixon; Laura A McAllister; Joseph T Barbieri; Saul Tzipori; Kim D Janda
Journal:  J Comb Chem       Date:  2006 Jul-Aug

6.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

7.  A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.

Authors:  Jiafu Wang; Tomas H Zurawski; Jianghui Meng; Gary Lawrence; Weredeselam M Olango; David P Finn; Larry Wheeler; J Oliver Dolly
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

8.  Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.

Authors:  Katerina Capková; Yoshiyuki Yoneda; Tobin J Dickerson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2007-10-09       Impact factor: 2.823

9.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

Authors:  Nicholas R Silvaggi; Grant E Boldt; Mark S Hixon; Jack P Kennedy; Saul Tzipori; Kim D Janda; Karen N Allen
Journal:  Chem Biol       Date:  2007-05

Review 10.  Neurotoxins affecting neuroexocytosis.

Authors:  G Schiavo; M Matteoli; C Montecucco
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

View more
  6 in total

1.  A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.

Authors:  Dejan Caglič; Kristin M Bompiani; Michelle C Krutein; Petr Čapek; Tobin J Dickerson
Journal:  J Vis Exp       Date:  2013-12-27       Impact factor: 1.355

2.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

3.  Systematic discovery of molecular probes targeting multiple non-orthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A).

Authors:  Saedeh Dadgar; Wely B Floriano
Journal:  Mol Cell Probes       Date:  2015-03-04       Impact factor: 2.365

Review 4.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Identification of Slow-Binding Inhibitors of the BoNT/A Protease.

Authors:  Ealin N Patel; Lewis D Turner; Mark S Hixon; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2022-03-08       Impact factor: 4.632

6.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.

Authors:  Dejan Caglič; Michelle C Krutein; Kristin M Bompiani; Deborah J Barlow; Galit Benoni; Jeffrey C Pelletier; Allen B Reitz; Luke L Lairson; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.